Figure 4

Abnormal expression of lncRNA GPNCA in colon and liver cancer. (A) GPNCA expression in different neoplasm disease stages of colon adenocarcinoma (Stage I, n = 75; Stage II, n = 176; Stage III, n = 128; Stage IV, n = 64), one-way ANOVA. (B) Expression of GPNCA in lymph node metastases positive (n = 171) or negative (n = 243) colon adenocarcinoma. (C) Analysis of GPCNA expression in distant metastasis negative (n = 308) and positive (n = 54) colon adenocarcinoma. Kaplan-Meier survival curves between GPNCA expression and (D) DFS (n = 455) and (E) RFS (n = 365) for colon adenocarcinoma. (F) GCPNA expression in early neoplasm disease stages (Stage I + Stage II, n = 255) and late neoplasm disease stages (Stage III + Stage IV, n = 84) for liver hepatocellular carcinoma. (G) Analysis of GPNCA expression in different differentiated grade tissues (G1 = 55, G2 = 177, G3 = 122, G4 = 12) of liver HCC. Kaplan-Meier survival curves between GPNCA expression and (H) disease-free survival (n = 364) or (I) recurrence-free survival (n = 190) for liver hepatocellular adenocarcinoma. *p < 0.05, **p < 0.01, ***p < 0.001.